Dorsey & Whitney Trust CO LLC Takes $257,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Dorsey & Whitney Trust CO LLC acquired a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 834 shares of the biopharmaceutical company’s stock, valued at approximately $257,000.

Several other large investors have also bought and sold shares of MDGL. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Madrigal Pharmaceuticals during the fourth quarter worth $70,000. Quest Partners LLC grew its position in Madrigal Pharmaceuticals by 172.8% during the 3rd quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 368 shares during the last quarter. KBC Group NV increased its holdings in Madrigal Pharmaceuticals by 73.5% in the 4th quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 258 shares in the last quarter. Miracle Mile Advisors LLC bought a new position in Madrigal Pharmaceuticals in the fourth quarter valued at about $216,000. Finally, D.A. Davidson & CO. acquired a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter valued at about $221,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Trading Up 1.9 %

Shares of MDGL stock opened at $335.39 on Wednesday. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $189.00 and a fifty-two week high of $377.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The stock has a 50 day simple moving average of $325.42 and a two-hundred day simple moving average of $289.11. The company has a market cap of $7.41 billion, a P/E ratio of -13.37 and a beta of -0.41.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share for the quarter, beating the consensus estimate of ($4.32) by $1.61. The company had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million. Research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, CEO William John Sibold sold 1,584 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $531,020.16. Following the completion of the sale, the chief executive officer now owns 54,303 shares of the company’s stock, valued at approximately $18,204,537.72. This trade represents a 2.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Rebecca Taub sold 1,689 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $273.41, for a total value of $461,789.49. Following the transaction, the chief marketing officer now directly owns 457,310 shares in the company, valued at $125,033,127.10. The trade was a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,900 shares of company stock valued at $12,168,079. Corporate insiders own 22.80% of the company’s stock.

Analyst Ratings Changes

MDGL has been the subject of several recent research reports. B. Riley raised Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and upped their price objective for the company from $236.00 to $422.00 in a research note on Thursday, February 27th. Citigroup upped their price target on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and set a $427.00 price target on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. Finally, HC Wainwright lifted their target price on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Madrigal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $375.75.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.